Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2015

View Archived Issues

Boehringer Ingelheim and MD Anderson Cancer Center collaborate in pancreatic ductal adenocarcinoma

Pfizer outlines the discovery of the myeloperoxidase inhibitor PF-06282999

NIAID reports results from phase I trial of anti-HIV antibody VRC-01

Adaptimmune and Universal Cells collaborate to develop universal allogeneic T-cell therapies

Novo Nordisk starts phase I trial comparing NNC-0143-0406 and insulin aspart

Phase II dose determined for tremelimumab plus gefitinib in EGFR-mutant NSCLC

Lilly's Portrazza available as first-line therapy for metastatic squamous NSCLC

First-in-human results lead to phase II planning for ABTL-0812

Ra Pharmaceuticals initiates phase I trial of complement C5 inhibitor RA-101495

Novel ADCs have a significant cytotoxic effect both in vitro and in vivo

Termination of Egalet's collaboration with Shionogi for S-718632

Biophytis Institut and Universite Pierre et Marie Curie patent GDF-8 inhibitors

Abide Therapeutics and Scripps Research Institute disclose MAGL inhibitors

Genzyme announces Nampt inhibitors

Allergan presents FPR2 ligands

FDA grants fast track designation to oliceridine for moderate to severe acute pain

Amgen files MAA for biosimilar adalimumab ABP-501

Coagadex now available in U.S.

FDA clears IND for study of Aramchol in patients with HIV-associated lipodystrophy and NAFLD

Sunesis establishes compassionate use program for vosaroxin in AML

Phase I studies evaluate repurposed mibefradil with radiotherapy or chemotherapy in glioma patients

Synthetic Biologics releases results from first phase IIa study of SYN-004

Novel enolase inhibitor shows in vivo antineoplastic activity

FDA grants rare pediatric disease designation to Kevetrin for retinoblastoma

Biovista begins drug repositioning collaboration with Astellas

Galenica confirms plans to split group in 2016